GA lesions, which form on the retina due to degeneration of pigment epithelium and photoreceptors, significantly impact daily functioning. This analysis assessed how functional and structural ...
The introduction of the first disease-modifying therapies fundamentally transformed the management of geographic atrophy and ...
FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...
Please provide your email address to receive an email when new articles are posted on . Retinal implants have a history of challenges, and questions remain about their utility. A bioengineered RPE ...
Add Yahoo as a preferred source to see more of our stories on Google. USC Roski Eye Institute researchers are launching a phase 2b trial of a stem cell retinal implant designed to replace damaged ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
SAN FRANCISCO -- A neuroprotective approach to geographic atrophy (GA) had a time-dependent effect on lesion growth and a significant impact on visual acuity, an early study showed. Overall, the ...
Si Hui Tan, PhD Director, Pipeline and Site Head, Singapore, Cirrus Therapeutics Ying Kai Chan, PhD Chief Executive Officer ...
BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10) BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5) Maintenance or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results